10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease

Rhea-AI Summary

10x Genomics (NASDAQ: TXG) announced a collaboration with Brigham & Women's Hospital on a blood‑based, single‑cell study of autoimmune diseases launched Jan 12, 2026. The study plans to enroll 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus and giant cell arteritis plus healthy controls, collecting peripheral blood at routine visits and pairing single‑cell Chromium Flex assays with longitudinal clinical data. The collaboration aims to identify immune signatures tied to disease activity, flare, remission and treatment response and to build a framework for a future clinical report. The program aligns with 10x's multi‑year effort, including a planned CLIA‑certified lab and other institutional partnerships.

Positive

• Plans to enroll 1,000 patients with RA, SLE and GCA
• Longitudinal peripheral blood sampling paired with clinical data
• Use of Chromium Flex single‑cell assays for immune mapping
• Collaboration with Brigham & Women's Hospital investigators
• Links to 10x's plan for a CLIA‑certified laboratory

Negative

• No validated clinical test or regulatory approval announced
• No timelines or milestones given for clinical implementation

News Market Reaction

-3.23%

34 alerts

-3.23% News Effect

-4.3% Trough in 25 min

-$82M Valuation Impact

$2.45B Market Cap

0.6x Rel. Volume

On the day this news was published, TXG declined 3.23%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.3% from its starting point during tracking. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $82M from the company's valuation, bringing the market cap to $2.45B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Planned enrollment: 1,000 patients

1 metrics

Planned enrollment 1,000 patients RA, SLE and GCA study with longitudinal blood sampling

Market Reality Check

Price: $23.19 Vol: Volume 3,870,770 is 1.73x...

high vol

$23.19 Last Close

Volume Volume 3,870,770 is 1.73x the 20-day average of 2,231,508, indicating elevated interest ahead of this announcement. high

Technical Price $20.46 is trading above the 200-day MA at $12.59 and sits close to the $20.72 52-week high.

Peers on Argus

TXG gained 6.07% while key peers were mixed: CERT -4.31%, SDGR -2.34%, OMCL +1.0...

TXG gained 6.07% while key peers were mixed: CERT -4.31%, SDGR -2.34%, OMCL +1.06%, PHR +0.47%, GDRX +0.72%. This points to a stock-specific reaction to the collaboration news rather than a sector-wide move.

Historical Context

5 past events · Latest: 2025-12-29 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2025-12-29	Conference participation	Neutral	+0.9%	Announcement of presentation at the 44th J.P. Morgan Healthcare Conference.
2025-11-18	Strategic consortium	Positive	-0.9%	Launch of ASTRA consortium to build a pan-cancer spatial atlas on Xenium.
2025-11-11	Conference participation	Neutral	+0.6%	Participation in Wolfe Research Healthcare Conference fireside chat.
2025-11-06	Quarterly earnings	Negative	-3.6%	Q3 2025 results with lower gross margin and declining YoY revenue.
2025-10-29	Product launch	Positive	-3.3%	Launch of next-generation Chromium Flex for higher-throughput single cell research.

Pattern Detected

Recent history shows that product and partnership news has sometimes been sold into, while earnings and conference participation have generally seen modest, directionally consistent moves.

Recent Company History

Over the last several months, 10x Genomics has combined product innovation with strategic collaborations and capital markets visibility. In Q3 2025, it reported revenue of $149.0M with a narrowed operating loss, followed by guidance for sequential growth. Product-wise, it launched a new Chromium Flex assay, and formed the ASTRA pan-cancer spatial atlas consortium. The company also maintained an active presence at investor conferences, including Wolfe Research and the 44th J.P. Morgan conference. Today’s autoimmune research collaboration extends this pattern of large-scale, translational partnerships.

Market Pulse Summary

This announcement highlights a large-scale collaboration to enroll 1,000 autoimmune patients and use...

Analysis

This announcement highlights a large-scale collaboration to enroll 1,000 autoimmune patients and use single-cell profiling to link blood-based immune signatures with disease activity and treatment response. It extends 10x Genomics’ strategy of partnering with leading academic centers on translational studies that may support future clinical use of single-cell and spatial technologies. Investors may watch for concrete outputs such as validated immune markers, progress toward clinical reporting frameworks, and how these efforts complement prior initiatives in oncology and spatial biology.

Key Terms

single cell, peripheral blood, rheumatoid arthritis, systemic lupus erythematosus, +3 more

7 terms

single cell medical

"Study aims to identify single cell immune signatures of disease activity"

Single cell refers to the study or use of an individual cell rather than averaging measurements across many cells. Like listening to a single voice in a crowded room, single-cell approaches reveal differences and rare cell types that bulk measurements hide. For investors, single-cell data can de-risk drug development and diagnostics by pinpointing precise targets, explaining why a therapy works or fails, and enabling more tailored products that may command premium pricing or faster regulatory paths.

peripheral blood medical

"to analyze peripheral blood samples from patients living with rheumatoid arthritis"

Peripheral blood is the blood circulating through a person’s veins and arteries that is commonly drawn from a limb for laboratory tests and analyses, as opposed to blood still inside organs or bone marrow. For investors it matters because many diagnostic tests, clinical trial measurements, and cell-based therapies rely on samples from peripheral blood—like checking highway traffic to judge overall system health—so results can affect trial outcomes, regulatory decisions, and commercial prospects.

rheumatoid arthritis medical

"patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)"

A long-term autoimmune disease that causes the immune system to mistakenly attack the lining of joints, leading to pain, swelling, stiffness and progressive joint damage; it can also affect other organs. For investors, it matters because the condition drives sustained demand for treatments, influences clinical trial and regulatory outcomes, and affects healthcare spending and workplace disability—so drug approvals, new therapies or cost shifts can materially change the market value of companies involved.

systemic lupus erythematosus medical

"patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)"

Systemic lupus erythematosus is a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissue, causing inflammation that can affect skin, joints, kidneys, heart, lungs and other organs. It matters to investors because disease severity, prevalence, and gaps in effective treatments drive demand for new drugs and diagnostics—think of it as a large, persistent market need where a successful therapy can change patient outcomes and create significant commercial value.

giant cell arteritis medical

"systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover"

Giant cell arteritis is an inflammatory disease that attacks the walls of large and medium arteries—often those supplying the head and eyes—causing pain, reduced blood flow and, in severe cases, vision loss. Think of it as the body’s supply pipes swelling and narrowing; for investors it matters because it defines a clear medical need that drives demand for diagnostics, treatments and clinical trials, shaping revenue potential, regulatory risk and valuation for companies working in this area.

single-cell profiling medical

"Using single-cell profiling of peripheral blood, this research collaboration aims"

Single-cell profiling is a laboratory technique that measures genes, proteins or other features in individual cells rather than averaging many together—think of taking individual portraits instead of a group photo. For investors, it matters because this detailed view can reveal new drug targets, more precise diagnostics and clearer evidence of how therapies work, which can change a biotech company’s development risks, timelines and potential market value.

clia-certified laboratory regulatory

"and plans to build a CLIA-certified laboratory, marking the beginning"

A CLIA-certified laboratory is a medical testing lab that meets U.S. federal standards for accuracy, reliability and quality control when performing human diagnostic tests. Think of it like a safety inspection or driver's license for labs: certification shows tests are run under approved procedures and oversight. For investors, CLIA certification reduces regulatory and operational risk, affects a lab’s ability to bill insurers and sell diagnostic services, and can influence revenue and growth potential.

AI-generated analysis. Not financial advice.

Study aims to identify single cell immune signatures of disease activity and treatment response to support clinical care

PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Brigham & Women's Hospital, a world-class academic medical center, to analyze peripheral blood samples from patients living with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and giant cell arteritis (GCA) to uncover immune signatures associated with disease activity, flare, remission and therapeutic response.

The study will be led by investigators Kevin Wei, MD, PhD, Jeffrey Sparks, MD, MMSc, Deepak Rao, MD, PhD, Paul Hoover, MD, PhD and Abigail Schiff, MD, PhD, all from the Division of Rheumatology, Inflammation and Immunity at Brigham and Women's Hospital, founding member of Mass General Brigham.

Autoimmune diseases remain among the most challenging conditions to diagnose and treat. Standard clinical tests provide only limited insight into the complex immune processes underlying these diseases and may be confounded by unrelated inflammation or masked by certain therapies. This level of uncertainty has led some experts to describe autoimmune disease management as a clinical 'random walk,' driven more by symptoms, nonspecific tests and experience, rather than by direct measures of immune activity, leaving clinicians without reliable tools to guide long-term care.

Using single-cell profiling of peripheral blood, this research collaboration aims to help address that gap by generating a high-resolution view of the dynamic immune signatures that drive autoimmune disease. The study plans to enroll 1,000 patients with RA, SLE or GCA, along with healthy controls, and follow them over an extended period with blood collection at routine clinical visits. Using 10x's Chromium Flex single-cell assay, investigators will create detailed molecular maps of circulating immune cells over the course of disease and treatment. By pairing these profiles with longitudinal clinical data, the collaboration seeks to identify immune features that distinguish controlled disease from active inflammation, responders from non-responders and flare from remission.

As part of this effort, 10x and Brigham & Women's Hospital also plan to build a framework for a future clinical report, defining how blood-based molecular features, such as immune activation patterns or markers of disease trajectory, could be translated into a clear, clinically relevant summary to support physicians as they evaluate disease activity and plan treatments for autoimmune disease.

"By incorporating single-cell genomics into routine clinical workflow, our goal is to transform the care of patients with autoimmune disease and enable personalized medicine in rheumatology," says co-Principal Investigator Dr. Wei.

This collaboration deepens 10x's broader effort to work with leading academic institutions on large-scale, translational studies designed to generate the evidence needed for future clinical applications of single-cell and spatial technologies. It follows 10x's recently announced partnership with Dana-Farber Cancer Institute and plans to build a CLIA-certified laboratory, marking the beginning of 10x's multi-year initiative to develop 10x technologies and services for improving patient care.

"Autoimmune diseases represent one of the largest unmet needs in medicine, where patients and clinicians often lack reliable tools to understand disease activity in real time," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "By collaborating with Brigham & Women's Hospital researchers, we intend to generate the scientific foundation necessary to support more informed clinical decisions. This collaboration is an important next step in our journey as a company and reflects our belief that single-cell technology can meaningfully improve the way complex diseases are understood and treated."

Additional studies and collaborations are being planned, each contributing to generating the foundational work needed to develop the future clinical potential of single-cell and spatial technologies.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics' products and collaborations. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x trademarks are the sole property of 10x, and are subject to legal protection in the United States and/or certain other countries.

Disclosure Information

10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-launches-study-to-advance-research-in-blood-based-diagnostics-for-autoimmune-disease-302657874.html

SOURCE 10x Genomics, Inc.

FAQ

What is the scope of 10x Genomics' Jan 12, 2026 autoimmune study (TXG)?

The study plans to enroll 1,000 patients with RA, SLE and GCA plus healthy controls, collecting blood at routine visits for single‑cell profiling.

Which technology will 10x Genomics use in the TXG autoimmune study?

Investigators will use 10x's Chromium Flex single‑cell assay to generate molecular maps of circulating immune cells.

Who is 10x Genomics partnering with for the TXG autoimmune research?

10x is collaborating with Brigham & Women's Hospital investigators from the Division of Rheumatology, Inflammation and Immunity.

What clinical outcomes is the TXG study aiming to identify?

The study aims to identify immune signatures associated with disease activity, flare, remission and therapeutic response.

Will the TXG study create a clinical report or test?

The collaboration plans to build a framework for a future clinical report, but no validated clinical test or approval was announced.

How does this TXG collaboration fit into 10x Genomics' broader plans?

It deepens 10x's multi‑year translational efforts and follows a partnership and plans to build a CLIA‑certified laboratory to support clinical applications.